Clinical Trials
12 trialsNCT00199030 2023-03-20
Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath
Goethe University
Phase 2 Completed
NCT00980395 2019-12-30
VCR
University of Arizona
Phase 2 Completed
NCT03318419 2019-08-20
Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia
Sun Yat-sen University
Phase 2 Unknown
NCT03602131 2018-07-26
Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma
Sichuan University
Phase 2 Unknown
NCT03151876 2018-07-18
Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma
Sichuan University
Phase 2 Unknown
NCT01446900 2018-01-31
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
European Institute of Oncology
Phase 2 Terminated
NCT00764517 2017-12-11
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00002879 2016-12-07
Cladribine in Patients With Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00053027 2016-12-07
Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00656812 2013-12-24
Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT00072007 2012-05-15
Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL
Swiss Cancer Institute
Phase 2 Completed
NCT01513603 2012-01-20
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
New York Medical College
Phase 2 Unknown